Physician profile
Roberto Lufschanowski
NPI 1063435907
$5,637.48
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $761 · 2021: $1,533 · 2022: $988 · 2023: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,435.47 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $470.44 | 2019-2022 | |
| Amgen INC. | $461.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $355.54 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $337.75 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $318.83 | 2019-2022 | |
| Pfizer INC. | $220.51 | 2019-2022 | |
| Esperion Therapeutics, INC. | $191.46 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $176.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $168.96 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $154.21 | 2021-2023 | Optimizer |
| Boston Scientific Corporation | $147.40 | 2022 | |
| Akcea Therapeutics, INC. | $141.84 | 2019-2020 | |
| Astellas Pharma US INC | $137.44 | 2019-2020 | |
| Abbott Laboratories | $123.30 | 2021-2023 | Cardiomems |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $118.13 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $106.77 | 2019-2021 | |
| Novo Nordisk INC | $87.57 | 2022 | |
| Merck Sharp & Dohme LLC | $68.38 | 2021-2022 | |
| Heartflow, INC. | $67.65 | 2019-2022 | |
| Biotronik INC. | $64.70 | 2021 | |
| Vifor Pharma, INC. | $49.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.08 | 2020 | |
| Avinger INC. | $20.41 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.20 | 2019 | |
| Irhythm Technologies, INC. | $13.41 | 2020 | |
| Medicure Pharma INC. | $11.78 | 2021 | |
| Medtronic, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Lufschanowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.